Last reviewed · How we verify

StrataGraft — Competitive Intelligence Brief

StrataGraft (StrataGraft) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Skin substitute. Area: Dermatology.

phase 3 Skin substitute Dermatology Biologic Live · refreshed every 30 min

Target snapshot

StrataGraft (StrataGraft) — Stratatech, a Mallinckrodt Company. StrataGraft is a bioengineered human skin substitute used to treat severe burns.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
StrataGraft TARGET StrataGraft Stratatech, a Mallinckrodt Company phase 3 Skin substitute

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Skin substitute class)

  1. Stratatech, a Mallinckrodt Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). StrataGraft — Competitive Intelligence Brief. https://druglandscape.com/ci/stratagraft. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: